Mildronate (3-(2,2,2-trimethylhydrazinium) propionate), which is mostly used in cardiological practice and is considered an anti-ischemic
drug, was designed to inhibit
carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of
fatty acid beta-oxidation. Recently it was shown that the mitochondrial respiratory chain may also be a target for
mildronate action. In this study, we aimed to investigate whether
mildronate can protect the liver against a 90-min normothermic
ischemia/30-min reperfusion-induced
mitochondrial dysfunction. Rats were pre-treated for one or two weeks with
mildronate (100 mg/kg/day or 200 mg/kg/day) or
Ringer solution and subjected to
ischemia/reperfusion.We found that
ischemia/reperfusion caused a decrease in mitochondrial State 3 respiration rate and in the respiratory control index (RCI), and an increase in State 2 respiration rate with
succinate,
glutamate +
malate and palmitoyl-
L-carnitine +
malate. One or two weeks of pre-treatment of rats with different doses of
mildronate did not reduce the
ischemia/reperfusion-induced decrease in the State 3 respiration rate or RCI; however, a one week pre-treatment slightly diminished the increase in the State 2 respiration rate with
glutamate +
malate substrates. The leakage of the liver
enzymes,
aspartate aminotransferase,
alanine aminotransferase and
lactate dehydrogenase, was similar in both the untreated and pre-treated with
mildronate groups. No steatotic livers were observed in any experimental groups after
mildronate pre-treatment. In conclusion, 90 min of liver
ischemia followed by a 30 min reperfusion has a deleterious effect on rat liver mitochondrial function.
Mildronate pre-treatment of rats at doses of 100 or 200 mg/kg/day for one or two weeks did not prevent
ischemia/reperfusion-induced
mitochondrial dysfunction and liver injury.